Noxopharm Loan Terms Amended to Benefit Company
Filed with ASX · · 3 pages · English
Story so far
Earlier from Noxopharm
- First COVID-19 Patient Treated in Veyonda Study
- Veyonda COVID-19 Study Approved For Immediate Start
- Appendix 4E and Audited Financial Statements FY2020
- Peer-Reviewed Publication Strengthens Case For Veyonda
- Noxopharm 2020 June quarter Appendix 4C & Activities Report
Later from Noxopharm
- Noxopharm Quarterly Activities Report & Appendix 4C
- Dedicated Septic Shock Company Established
- Veyonda To Be Tested In Combination With Opdivo In Trial
- Independent Discovery Validates DARRT Cancer Therapy
- Noxopharm Completes A$23m Placement to Fund Clinical Studies
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm